Pyrazinamide warnings and precautions: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Pyrazinamide }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIK...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==WARNINGS== | |||
Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely. | |||
Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
Revision as of 01:32, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
WARNINGS
Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely.
Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.[1]
References
Adapted from the FDA Package Insert.